Sofosbuvir, a new drug, is offering impressive cure rates for Hepatitis C patients with two subtypes of the disease - genotypes 2 and 3, according to researchers led by Weill Cornell Medical College. Approximately 1 in every 4 hepatitis C patients in the USA has one of these two subtypes. Sofosbuvir, which is much safer than Interferon, offered more effective treatment for the majority of patients involved in a Phase 3 clinical trial. The participants had no other treatment options, the scientists reported in NEJM (New England Journal of Medicine)...
More...
More...